Seattle-based biotech company HDT Bio closed a seed round totaling roughly $3 million to support work on its COVID-19 vaccine candidate HDT-301.
Researchers from HDT Bio and the University of Washington in July published a rapid-release paper in the
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly